Stay updated on Daratumumab in AL Amyloidosis Clinical Trial
Sign up to get notified when there's something new on the Daratumumab in AL Amyloidosis Clinical Trial page.

Latest updates to the Daratumumab in AL Amyloidosis Clinical Trial page
- Check6 days agoNo Change Detected
- Check13 days agoChange DetectedAdded detailed quality-of-life assessment details for EORTC QLQ-C30 and SF-36, including baseline and multiple follow-up timepoints. The update also enumerates the items and scoring methods used in these QoL instruments.SummaryDifference1%

- Check20 days agoChange DetectedPublication entries are now described as auto-filled from PubMed and may not be about the study. The page revision is updated to v3.3.2 (the previous revision was v3.2.0). To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check27 days agoChange DetectedNotice about government funding and operating status was removed from the page. Other study details and location information remain unchanged.SummaryDifference0.2%

- Check42 days agoChange DetectedNo significant changes detected in core study information (design, eligibility criteria, endpoints, enrollment) between the two screenshots; observed differences appear to be minor or formatting-related. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.2%

- Check71 days agoChange DetectedAdded a government-status notice and a v3.2.0 revision; removed the v3.1.0 revision. The page now informs users about potential delays and where to check current operating status, and indicates the new version.SummaryDifference2%

- Check78 days agoChange DetectedChanged the revision from v3.0.2 to v3.1.0, indicating a minor version update with no substantive content changes.SummaryDifference0.1%

Stay in the know with updates to Daratumumab in AL Amyloidosis Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Daratumumab in AL Amyloidosis Clinical Trial page.